Member Info for Yorkshirepragma

Add in the potential efficacy of FAP release Affimer conjugates , plus ease of production & !?

Watch this space for a deal.

BV, reread this .sorry must check better ..my greatest .apologies …m’st b’to’old peck ont Frydaay

Bon weekend…

Mav…not only that BP s always ‘ fishing’ in a small pond. This one could bite at any time…

M&A this development position at $1-2bn with fair science on display.

If this is tempting anyone,then it s 8n a good position currently for the buyer , not necessarily the board and shareholders tho!

Could be soon , could be later.. that’s fishing.

Https://www.genengnews.com/topics/cancer/novartis-to-acquire-morphosys-for-2-9b-bolstering-oncology-pipeline/

& on the oncology M&A front..

-Phase 2 not a turn off provided +ve trend

- ‘ success’ means reduction/ disease stasis not complete ‘ cure’

- BP not averse to a punt.

-

A great tracker site .

A new entry every 1-2 weeks !

Who knows …we don’t!

https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/

If an offer coming then $1-2bn at this point.

Here’s to the future ,whatever….

GLA

Just add if it’s a low ball, clean up the shop offer I’d be unhappy too…

Lot of conjecture here on AS .

IMHE. Either financial backers sought this , OR Alastair disagreed with an approach proposal which is warming up and being supported by remaining board.

Happens a lot.

Wish AS well, it’s no mean feat to start a company like this and see it through to a decent stage .

GLA

Wheels within wheels now…..

Https://www.marianaoncology.com/our-science/

Https://www.biopharmadive.com/trendline/oncology-cancer-research/63/?utm_source=BPC&utm_medium=BlastMay1&utm_campaign=EVERSANA

Warming up in 24

Https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/

Could happen in a trice….

Numerous discussions..vip!

Obviously….!

Trails are modified by panels a lot outside control , and hope it’s all go from here.

Certainly the high FAP areas are responding .

We’ll see…

Tout, Chat relies on inputs and when this changes ,eg new info, thence all changes.

Last point on low FAP result being least efficacious, was expected.

& data on high FAP tumours represent a sig. result .

Any BP would be delighted to have this in their res portfolio at this stage.

I worked for this area so reflective experience.

Sad to see such bad rhetoric towards AS et al.

Undeserved UK Biotech support is NVG market wise , this is playing a big part here.

GLA on a cold Sunday morning. Now where’s the Yorkshire Gokd tea as?

Ice, likely if not certain.

Https://avacta.wistia.com/medias/b74537ezmn

This presentation rather tucked away in the ‘ other resources’.

It’s the most telling summary delivered well.

Investors should review .

Sound.

Https://www.pfizer.com/news/articles/speeding_up_the_drug_approval_process_and_what_that_means_for_patients